Kevin S Kapner

10PUBLICATIONS
196CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 08, 2025
Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition.

Zackery A Ely, Zachary J Kulstad, Gurcan Gunaydin

|Sep 16, 2024
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer.

Harshabad Singh, Joanne Xiu, Kevin S Kapner

|Jul 08, 2024
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.

Julien Dilly, Megan T Hoffman, Laleh Abbassi

|Feb 12, 2024
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.

Harshabad Singh, Pranshu Sahgal, Kevin Kapner

|Jan 18, 2024
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.

Douglas A Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz

|Oct 11, 2023
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.

Brandon M Huffman, Hanrong Feng, Kalindi Parmar

Pageof 2